Search clinical trials for: Mixed Hyperlipidemia

Total 4906 results

Novartis Pharmaceuticals

Not yet recruiting

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Mixed Dyslipidemia | Primary Hypercholesterolemia

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Novartis Pharmaceuticals

Recruiting

Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL)

Mixed Dyslipidemia | Primary Hypercholesterolemia

Switzerland, Saudi Arabia, United Arab Emirates, United Kingdom, Austria, Israel, China, Malaysia
Novartis Pharmaceuticals

Recruiting

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Hypercholesterolemia | Mixed Dyslipidemia

Austria, United Kingdom, Italy, Germany, Belgium
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Eli Lilly and Company

Active, not recruiting

A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipoproteinemia

United States, Mexico, Poland, Canada, Turkey, Japan, Argentina
Brigham and Women's Hospital

Active, not recruiting

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (LDL-ALERT)

ASCVD | Hyperlipemia, Mixed

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Mixed Hyperlipidemia | Non-familial Hypercholesterolemia

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Emory University
Centers for Disease Control and Prevention

Completed

The Mixed Meal Challenge Study

Cardiovascular Diseases | Hyperlipidemias

United States
Amgen

Terminated

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Sanofi

Completed

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS)

Atherosclerotic Cardiovascular Disease | Primary Hypercholesterolaemia and Mixed Dyslipidaemia

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
Amgen

Completed

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Amgen

Completed

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Hyperlipidemia | Mixed Dyslipidemia

United States
Pfizer
TIMI Study Group

Completed

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Dyslipidemias | Hyperlipidemias | Hyperlipoproteinemias

United States, Canada, Poland
Amgen

Completed

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection

Canada, France, United States, Belgium, Italy, Spain, Switzerland, United Kingdom, South Africa, Portugal, Australia, Greece, Brazil, Romania, Poland
Orient Pharma Co., Ltd.

Completed

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Primary Hypercholesterolemia | Mixed Dyslipidemias

Taiwan, Australia, New Zealand
Organon and Co

Completed

A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)

Hypercholesterolemia | Hypertriglyceridemia | Hyperlipidemia
Organon and Co

Completed

Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)

Hypercholesterolemia | Hypertriglyceridemia
Organon and Co

Completed

Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

Hypercholesterolemia | Hypertriglyceridemia
Korea United Pharm. Inc.

Active, not recruiting

Study to Evaluate the Safety and PK of UI018

Hyperlipemia, Mixed

Korea, Republic of
Misr University for Science and Technology

Active, not recruiting

Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

Hyperlipidemia; Mixed

Egypt
University of Guelph
Canadian Agricultural Partnership Pulse Science Cluster Program; The Bonduelle...

Completed

Effect of Canned Beans of Multiple Varieties in Daily Amounts of 1 Cup and 1/2 Cup on Serum LDL Cholesterol and Other Cardiovascular Disease Risk Biomarkers in Adults With Elevated LDL Cholesterol

Cardiovascular Diseases | Hypercholesterolemia

Canada
National University, Singapore
National University Health System, Singapore

Completed

Black Rice Anthocyanin in Mixed Meals: Influence on Postprandial Glycaemic and Lipid Responses Among Healthy Individuals

Postprandial Hyperglycemia | Lipidemia

Singapore
Kowa Research Institute, Inc.

Withdrawn

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
Kowa Research Institute, Inc.

Withdrawn

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Ache Laboratorios Farmaceuticos S.A.

Completed

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia (LANCE)

Dyslipidemia | Hypercholesterolemia

Brazil
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Merck Sharp & Dohme LLC

Completed

MK-0524B Lipid Study (MK-0524B-063)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Amgen

Completed

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Diabetes, Hyperlipidemia, Mixed Dyslipidemia

United States, Canada, France, Korea, Republic of, China, Argentina, Russian Federation, Colombia, Turkey, Brazil
Amgen

Completed

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Amgen

Completed

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Primary Hyperlipidemia and Mixed Dyslipidemia

Australia
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Mixed Hyperlipidemia
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
SingHealth Polyclinics
Agency for Science, Technology and Research

Unknown

Health Outcomes of Patients With Stable Chronic Disease Managed With a Healthcare Kiosk

Hypertension | Diabetes Mellitus | Hyperlipidemia; Mixed

Singapore
Huazhong University of Science and Technology

Unknown

The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism (PUFA)

Hyperlipidemias

China
Pfizer

Completed

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia (SPIRE-AI)

Hyperlipidemia

United States
Pfizer

Withdrawn

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects (SPIRE-ASIA)

Primary Hyperlipidemia or Mixed Dyslipidemia

China

3

Subscribe